Ingalls & Snyder LLC’s Champions Oncology CSBR Stock Holding History

Ingalls & Snyder LLC’s Portfolio CSBR Stock Details CSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,056	Closed	-$44K	–	438
2023 Q1	$44K	Hold	11,056	–	–	﹤0.01%	419
2022 Q4	$50K	Hold	11,056	–	–	﹤0.01%	429
2022 Q3	$83K	Hold	11,056	–	–	﹤0.01%	412
2022 Q2	$88K	Hold	11,056	–	–	﹤0.01%	427
2022 Q1	$90K	Hold	11,056	–	–	﹤0.01%	447
2021 Q4	$92K	Hold	11,056	–	–	﹤0.01%	457
2021 Q3	$113K	Hold	11,056	–	–	0.01%	447
2021 Q2	$114K	Hold	11,056	–	–	0.01%	449
2021 Q1	$125K	Sell	11,056 -6,000	-35%	-$69.6K	0.01%	425
2020 Q4	$184K	Hold	17,056	–	–	0.01%	406
2020 Q3	$158K	Hold	17,056	–	–	0.01%	348
2020 Q2	$163K	Sell	17,056 -115,769	-87%	-$987K	0.01%	377
2020 Q1	$983K	Hold	132,825	–	–	0.07%	198
2019 Q4	$1.11M	Hold	132,825	–	–	0.06%	191
2019 Q3	$750K	Sell	132,825 -13,221	-9%	-$85.8K	0.04%	245
2019 Q2	$1.14M	Sell	146,046 -12,602	-8%	-$111K	0.06%	208
2019 Q1	$1.55M	Hold	158,648	–	–	0.07%	179
2018 Q4	$1.24M	Hold	158,648	–	–	0.07%	187
2018 Q3	$2.77M	Buy	+158,648	New	+$1.41M	0.12%	139

Other funds holding CSBR

BMC

Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ingalls & Snyder LLC's CSBR Position: Q2 2023 in Review

Ingalls & Snyder LLC sold out of Champions Oncology (CSBR) in Q2 2023, closing a stake of 11,056 shares — an estimated $44K sold.

Ingalls & Snyder LLC first reported a position in CSBR in Q3 2018 and held it in 19 quarters. The position peaked at $2.77M in Q3 2018. 28 funds tracked by Wall St. Rank hold CSBR as of Q2 2023.

Ingalls & Snyder LLC reported no remaining Champions Oncology position as of Q2 2023 after selling out during the quarter.
Ingalls & Snyder LLC sold 11,056 Champions Oncology shares in Q2 2023, an estimated $44K.
Ingalls & Snyder LLC first reported a position in Champions Oncology in Q3 2018 and held it in 19 quarters.
Ingalls & Snyder LLC's Champions Oncology position peaked at $2.77M in Q3 2018.
28 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2023.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2023, filed 27 Jul 2023.